CROSSJECT remains engaged during the summer break

Core Points - CROSSJECT is actively working on submitting the ZEPIZURE® dossier for Emergency Use Authorization (EUA) despite the summer break [3][4] - Maintenance operations are ongoing at CROSSJECT's three production sites to ensure optimal conditions for future commercial deliveries [4][9] - Development teams are engaged in preparations for the New Drug Application (NDA) for ZEPIZURE®, including monitoring production and planning additional clinical studies in the United States [5][6] Company Overview - CROSSJECT is a specialty pharmaceutical company focused on emergency products utilizing its ZENEO® needle-free auto-injector technology [3][7] - The company has a $60 million contract with BARDA for the development of ZEPIZURE®, an epileptic rescue therapy [7][8] - The ZENEO® platform allows for easy and instant delivery of emergency medications, targeting various conditions including allergic shocks and adrenal insufficiencies [7]